Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | terminated | Phase 1 / Phase 2 | 57 | Jennifer AmengualOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 |
| clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | terminated | Phase 1 | 22 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | terminated | Phase 1 | 58 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT04788043 | Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma | terminated | Phase 2 | 8 | Ranjana AdvaniOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma(RELATIVITY-069) | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT04758650 | Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis(MITRAS) | terminated | Phase 2 | 29 | Universitair Ziekenhuis BrusselOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03246906 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | terminated | Phase 2 | 150 | Fred Hutchinson Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06870487 | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers | terminated | Phase 1 | 6 | PfizerINDUSTRY | 2 | May 8, 2026 | clinicaltrials |
| NCT05605119 | First in Human, Dose Escalation, Dose Expansion Study of AUR105(SURYA-1) | terminated | Phase 1 | 17 | Aurigene Discovery Technologies LimitedINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04486391 | Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma | terminated | Phase 3 | 3 | BeiGeneINDUSTRY | 1 | Mar 2, 2026 | clinicaltrials |
| NCT05938127 | Impact of Respiratory Training in Lymphoma Survivors | terminated | N/A | 1 | University of Colorado, DenverOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | terminated | Phase 1 | 79 | National Cancer Institute (NCI)NIH | 2 | Jan 21, 2026 | clinicaltrials |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | terminated | Phase 2 | 255 | Seagen Inc.INDUSTRY | 6 | Aug 28, 2025 | clinicaltrials |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas(NAVAL-1) | terminated | Phase 2 | 102 | Viracta Therapeutics, Inc.INDUSTRY | 14 | Jul 28, 2025 | clinicaltrials |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | terminated | Phase 1 / Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT01532635 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | terminated | Phase 2 | 4 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03615105 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | terminated | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | terminated | Phase 1 | 133 | Seagen Inc.INDUSTRY | 6 | Feb 10, 2025 | clinicaltrials |
| NCT05181540 | A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation(E-CELERATE) | terminated | Phase 3 | 130 | Angiocrine BioscienceINDUSTRY | 1 | Feb 4, 2025 | clinicaltrials |
| NCT01998035 | Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | terminated | Phase 1 / Phase 2 | 58 | Columbia UniversityOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT03198234 | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders(T-allo10) | terminated | Phase 1 | 5 | Roncarolo, Maria Grazia, MDOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | terminated | N/A | 24 | Washington University School of MedicineOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT00838955 | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma | terminated | Phase 2 | 14 | Loyola UniversityOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT02624388 | Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)(UVA-Gen001) | terminated | Phase 2 | 4 | University of VirginiaOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03495713 | Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS | terminated | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03138499 | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,(CheckMate 812) | terminated | Phase 3 | 23 | Bristol-Myers SquibbINDUSTRY | 3 | Jan 10, 2024 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04621604 | Evaluation of the Relationship Between Anti-PD-1 Exposure and Tumour VOLUME in Patients Treated for Classical HODgkin's Lymphoma.(REVOLUMHOD) | terminated | N/A | 7 | Rennes University HospitalOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03947255 | A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | terminated | Phase 2 | 12 | Seagen Inc.INDUSTRY | 1 | Oct 13, 2023 | clinicaltrials |
| NCT03776864 | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | terminated | Phase 2 | 6 | University of WashingtonOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | terminated | Phase 1 | 159 | Seagen Inc.INDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT01028716 | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 46 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT00496431 | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients | terminated | Phase 1 / Phase 2 | 19 | ItalfarmacoINDUSTRY | 1 | Jan 27, 2022 | clinicaltrials |
| NCT01468311 | Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2021 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT00992030 | R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma | terminated | Phase 3 | 112 | Fondazione MichelangeloOTHER | 2 | Aug 19, 2021 | clinicaltrials |
| NCT02867618 | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | terminated | Phase 1 / Phase 2 | 14 | Columbia UniversityOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response | terminated | N/A | 52 | WepromOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT00176930 | Stem Cell Transplant for Hematological Malignancy | terminated | N/A | 330 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | terminated | Phase 1 | 5 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients(TXA127-PBSC) | terminated | Phase 2 | 75 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
Data updated 13 days agoSource updated Sep 16, 2026source: clinicaltrials